IL10RA (Q13651) variants and mutations
IL10RA (also known as Q13651) is a human protein-coding gene encoding an interleukin-10 receptor subunit alpha protein. It is required for cells to respond to the anti-inflammatory cytokine IL-10 and activate downstream STAT3 signaling. Biallelic loss-of-function variants cause severe infantile or very-early-onset inflammatory bowel disease, often with perianal disease and systemic inflammation. This analysis covers 865 IL10RA variants and mutations. Of these, 94% have computational variant effect predictions. Disease context includes Autosomal recessive early-onset inflammatory bowel disease, IL10-related early-onset inflammatory bowel disease, and inflammatory bowel disease. Example IL10RA variants include L2L, L2M, and L2Q.
Variant analysis overview
- Gene: IL10RA
- Protein: Q13651
- UniProt accession: Q13651
- Organism: Homo sapiens
- Variants analyzed: 865
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 697 unspecified-consequence records; 63 synonymous variants; 91 missense variants; 1 in-frame deletions; 3 stop-gained variants; 3 splice-region variants; 4 frameshift variants; 1 in-frame insertions; 2 substitution
- Prediction scores: 812 variants have prediction scores (94% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Autosomal recessive early-onset inflammatory bowel disease, IL10-related early-onset inflammatory bowel disease, inflammatory bowel disease, ulcerative colitis, cervical carcinoma, pancreatic ductal adenocarcinoma, pancreatic adenocarcinoma, malignant pancreatic neoplasm, eye injury, hereditary disease, colitis, neoplasm.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 6 post-translational modification sites.
- Structural context: 24 variants have structural context.
- PTM context: 11 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable IL10RA variants
Examples include L2L, L2M, L2Q, L2P, P3Q, P3R, P3S, P3T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2L (p.Leu2Leu), gnomAD 11-117986471-C-T, CADD 10.30
- L2M (p.Leu2Met), gnomAD 11-117986471-C-A, REVEL 0.21, MetaLR 0.39
- L2Q (p.Leu2Gln), gnomAD 11-117986472-T-A, REVEL 0.35, MetaLR 0.42
- L2P (p.Leu2Pro), gnomAD 11-117986472-T-C, REVEL 0.46, MetaLR 0.42
- P3Q (p.Pro3Gln), rs56008037, ClinGen CA6298789, ClinVar RCV000913660, 1000Genomes rs56008037, REVEL 0.22, MetaLR 0.18, Likely benign, Inflammatory bowel disease 28
- P3R (p.Pro3Arg), rs56008037, ClinGen CA6298790, ClinVar RCV001218593, 1000Genomes rs56008037, REVEL 0.11, MetaLR 0.14, Uncertain significance, Inflammatory bowel disease 28
- P3S (p.Pro3Ser), gnomAD rs1409311372, REVEL 0.17, MetaLR 0.10
- P3T (p.Pro3Thr), gnomAD 11-117986474-C-A, REVEL 0.14, MetaLR 0.14
- P3L (p.Pro3Leu), gnomAD 11-117986475-C-T, REVEL 0.13, MetaLR 0.10
- P3P (p.Pro3Pro), gnomAD 11-117986476-G-C, CADD 8.57
- C4* (p.Cys4Ter), TOPMed rs2057986658, CADD 34.00
- C4R (p.Cys4Arg), Ensembl rs2057986596, REVEL 0.12, MetaLR 0.05
- C4Y (p.Cys4Tyr), gnomAD rs1159235572, REVEL 0.17, MetaLR 0.10
- C4G (p.Cys4Gly), gnomAD 11-117986477-T-G, REVEL 0.12, MetaLR 0.08
- C4S (p.Cys4Ser), gnomAD 11-117986477-T-A, REVEL 0.10, MetaLR 0.09
- C4F (p.Cys4Phe), gnomAD 11-117986478-G-T, REVEL 0.16, MetaLR 0.10
- C4C (p.Cys4Cys), gnomAD 11-117986479-C-T, CADD 9.69
- L5F (p.Leu5Phe), rs1390054292, ClinGen CA382771846, ClinVar RCV002610842, TOPMed rs1390054292, REVEL 0.31, MetaLR 0.37, Uncertain significance, Inflammatory bowel disease 28
- L5I (p.Leu5Ile), gnomAD 11-117986480-C-A, REVEL 0.21, MetaLR 0.35
- L5P (p.Leu5Pro), gnomAD 11-117986481-T-C, REVEL 0.40, MetaLR 0.35
- L5L (p.Leu5Leu), gnomAD 11-117986482-C-A, CADD 5.81
- V6A (p.Val6Ala), rs768177135, ClinGen CA6298791, ClinVar RCV001926006, ExAC rs768177135, REVEL 0.09, MetaLR 0.17, Uncertain significance, Inflammatory bowel disease 28
- V6I (p.Val6Ile), TOPMed rs989694807, gnomAD rs989694807, REVEL 0.11, MetaLR 0.17, Uncertain significance
- V6L (p.Val6Leu), rs989694807, ClinGen CA229439384, ClinVar RCV000815632, ClinVar RCV006279231, REVEL 0.10, MetaLR 0.10, Uncertain significance, not provided; Inflammatory bowel disease 28
- V6V (p.Val6Val), gnomAD 11-117986485-A-G, CADD 3.98
- V7E (p.Val7Glu), rs2057986809, ClinGen CA382771884, ClinVar RCV001049526, Ensembl rs2057986809, REVEL 0.51, MetaLR 0.37, Uncertain significance, Inflammatory bowel disease 28
- V7L (p.Val7Leu), gnomAD 11-117986486-G-T, REVEL 0.19, MetaLR 0.22
- V7A (p.Val7Ala), gnomAD 11-117986487-T-C, REVEL 0.16, MetaLR 0.23
- V7V (p.Val7Val), gnomAD 11-117986488-G-T, CADD 11.90
- L8M (p.Leu8Met), gnomAD 11-117986489-C-A, REVEL 0.26, MetaLR 0.36
- L8L (p.Leu8Leu), gnomAD 11-117986489-C-T, CADD 12.40
- L9L (p.Leu9Leu), rs886047706, gnomAD 11-117986492-C-T, CADD 13.90
- L9M (p.Leu9Met), gnomAD 11-117986492-C-A, REVEL 0.42, MetaLR 0.58
- L9P (p.Leu9Pro), gnomAD 11-117986493-T-C, REVEL 0.62, MetaLR 0.60
- A10G (p.Ala10Gly), gnomAD rs2057986903, REVEL 0.13, MetaLR 0.22
- A10V (p.Ala10Val), gnomAD rs2057986903, REVEL 0.10, MetaLR 0.13
- A10S (p.Ala10Ser), gnomAD 11-117986495-G-T, REVEL 0.12, MetaLR 0.22
- A10T (p.Ala10Thr), gnomAD 11-117986495-G-A, REVEL 0.12, MetaLR 0.16
- A10E (p.Ala10Glu), gnomAD 11-117986496-C-A, REVEL 0.45, MetaLR 0.34
- A10A (p.Ala10Ala), rs1279259144, gnomAD 11-117986497-G-A, CADD 11.90
- A11T (p.Ala11Thr), gnomAD 11-117986498-G-A, REVEL 0.10, MetaLR 0.20
- A11S (p.Ala11Ser), gnomAD 11-117986498-G-T, REVEL 0.19, MetaLR 0.15
- A11V (p.Ala11Val), gnomAD 11-117986499-C-T, REVEL 0.08, MetaLR 0.23
- A11E (p.Ala11Glu), gnomAD 11-117986499-C-A, REVEL 0.49, MetaLR 0.39
- A11A (p.Ala11Ala), gnomAD 11-117986500-G-T, CADD 10.10
- L12F (p.Leu12Phe), gnomAD 11-117986501-C-T, REVEL 0.13, MetaLR 0.25
- L12I (p.Leu12Ile), gnomAD 11-117986501-C-A, REVEL 0.14, MetaLR 0.20
- L12P (p.Leu12Pro), gnomAD 11-117986502-T-C, REVEL 0.56, MetaLR 0.50
- L12L (p.Leu12Leu), gnomAD 11-117986503-C-A, CADD 5.95
- L13F (p.Leu13Phe), rs2057987183, ClinGen CA382771975, ClinVar RCV001339319, Ensembl rs2057987183, REVEL 0.28, MetaLR 0.51, Uncertain significance, Inflammatory bowel disease 28
- L13H (p.Leu13His), TOPMed rs2057987204, gnomAD rs2057987204, REVEL 0.41, MetaLR 0.53
- L13del (p.Leu13del), rs1565369886, gnomAD 11-117986500-GCTC, CADD 15.90
- L13I (p.Leu13Ile), gnomAD 11-117986504-C-A, REVEL 0.23, MetaLR 0.48
- L13P (p.Leu13Pro), gnomAD 11-117986505-T-C, REVEL 0.53, MetaLR 0.48
- L13L (p.Leu13Leu), gnomAD 11-117986506-C-A, CADD 8.26
- S14G (p.Ser14Gly), gnomAD 11-117986507-A-G, REVEL 0.16, MetaLR 0.31
- S14I (p.Ser14Ile), gnomAD 11-117986508-G-T, REVEL 0.44, MetaLR 0.41
- S14T (p.Ser14Thr), gnomAD 11-117986508-G-C, REVEL 0.23, MetaLR 0.24
- S14N (p.Ser14Asn), gnomAD 11-117986508-G-A, REVEL 0.31, MetaLR 0.45
- S14R (p.Ser14Arg), gnomAD 11-117986509-C-A, REVEL 0.53, MetaLR 0.47
- L15P (p.Leu15Pro), rs1452066804, ClinGen CA382771999, ClinVar RCV002943874, TOPMed rs1452066804, REVEL 0.55, MetaLR 0.50, Uncertain significance, Inflammatory bowel disease 28
- L15R (p.Leu15Arg), TOPMed rs1452066804, gnomAD rs1452066804, REVEL 0.48, MetaLR 0.35, Uncertain significance
- L15I (p.Leu15Ile), gnomAD 11-117986510-C-A, REVEL 0.34, MetaLR 0.46
- L15H (p.Leu15His), gnomAD 11-117986511-T-A, REVEL 0.48, MetaLR 0.48
- L15L (p.Leu15Leu), rs1230361448, gnomAD 11-117986512-C-T, CADD 7.22
- R16C (p.Arg16Cys), rs748428395, ClinGen CA6298793, ClinVar RCV001035429, ExAC rs748428395, REVEL 0.12, MetaLR 0.17, Uncertain significance, Inflammatory bowel disease 28
- R16G (p.Arg16Gly), ExAC rs748428395, TOPMed rs748428395, gnomAD rs748428395, REVEL 0.18, MetaLR 0.13, Uncertain significance
- R16H (p.Arg16His), ESP rs75769905, ExAC rs75769905, TOPMed rs75769905, gnomAD rs75769905, REVEL 0.20, MetaLR 0.19, Uncertain significance
- R16L (p.Arg16Leu), ESP rs75769905, ExAC rs75769905, TOPMed rs75769905, gnomAD rs75769905, REVEL 0.14, MetaLR 0.17, Uncertain significance
- R16P (p.Arg16Pro), rs75769905, ClinGen CA6298794, ClinVar RCV001054870, ClinVar RCV004031735, REVEL 0.35, MetaLR 0.18, Uncertain significance, Inborn genetic diseases; Inflammatory bowel disease 28
- R16S (p.Arg16Ser), ExAC rs748428395, TOPMed rs748428395, gnomAD rs748428395, REVEL 0.05, MetaLR 0.11, Uncertain significance
- R16R (p.Arg16Arg), gnomAD 11-117986515-T-C, CADD 7.40
- L17F (p.Leu17Phe), Ensembl rs75911988, REVEL 0.10, MetaLR 0.17
- L17I (p.Leu17Ile), gnomAD 11-117986516-C-A, REVEL 0.18, MetaLR 0.15
- L17H (p.Leu17His), gnomAD 11-117986517-T-A, REVEL 0.21, MetaLR 0.14
- L17P (p.Leu17Pro), gnomAD 11-117986517-T-C, REVEL 0.18, MetaLR 0.11
- L17L (p.Leu17Leu), gnomAD 11-117986518-T-C, CADD 3.59
- G18S (p.Gly18Ser), gnomAD 11-117986519-G-A, REVEL 0.23, MetaLR 0.30
- G18C (p.Gly18Cys), gnomAD 11-117986519-G-T, REVEL 0.20, MetaLR 0.29
- G18V (p.Gly18Val), gnomAD 11-117986520-G-T, REVEL 0.21, MetaLR 0.22
- G18D (p.Gly18Asp), gnomAD 11-117986520-G-A, REVEL 0.44, MetaLR 0.27
- G18G (p.Gly18Gly), gnomAD 11-117986521-C-G, CADD 7.14
- S19P (p.Ser19Pro), Ensembl rs1565369907, REVEL 0.10, MetaLR 0.22
- S19T (p.Ser19Thr), gnomAD 11-117986522-T-A, REVEL 0.10, MetaLR 0.21
- S19* (p.Ser19Ter), gnomAD 11-117986523-C-A, CADD 34.00
- S19L (p.Ser19Leu), gnomAD 11-117986523-C-T, REVEL 0.12, MetaLR 0.25
- S19S (p.Ser19Ser), gnomAD 11-117986524-A-T, CADD 4.12
- D20N (p.Asp20Asn), gnomAD 11-117986525-G-A, REVEL 0.05, MetaLR 0.21
- D20Y (p.Asp20Tyr), gnomAD 11-117986525-G-T, REVEL 0.13, MetaLR 0.19
- D20H (p.Asp20His), gnomAD 11-117986525-G-C, REVEL 0.08, MetaLR 0.20
- D20D (p.Asp20Asp), rs1280632982, gnomAD 11-117986527-C-T, CADD 7.29
- D20E (p.Asp20Glu), gnomAD 11-117986527-C-A, REVEL 0.04, MetaLR 0.20
- A21T (p.Ala21Thr), gnomAD rs1442855942, REVEL 0.29, MetaLR 0.26
- A21V (p.Ala21Val), TOPMed rs1288585880, gnomAD rs1288585880, REVEL 0.38, MetaLR 0.35
- A21S (p.Ala21Ser), gnomAD 11-117986528-G-T, REVEL 0.24, MetaLR 0.29
- A21P (p.Ala21Pro), gnomAD 11-117986528-G-C, REVEL 0.51, MetaLR 0.43
- A21D (p.Ala21Asp), gnomAD 11-117986529-C-A, REVEL 0.51, MetaLR 0.45
- A21A (p.Ala21Ala), gnomAD 11-117986530-T-A, CADD 6.50
- H22L (p.His22Leu), gnomAD rs1249233978, REVEL 0.24, MetaLR 0.23, Uncertain significance
- H22N (p.His22Asn), gnomAD rs1203522961, REVEL 0.18, MetaLR 0.25
- H22P (p.His22Pro), rs1249233978, ClinGen CA382772038, ClinVar RCV001947356, gnomAD rs1249233978, REVEL 0.41, MetaLR 0.31, Uncertain significance, Inflammatory bowel disease 28
- H22Q (p.His22Gln), TOPMed rs1483805691, gnomAD rs1483805691, REVEL 0.13, MetaLR 0.25
- H22R (p.His22Arg), gnomAD rs1249233978, REVEL 0.20, MetaLR 0.28, Uncertain significance
- H22Y (p.His22Tyr), gnomAD rs1203522961, REVEL 0.19, MetaLR 0.20
- H22D (p.His22Asp), gnomAD 11-117986531-C-G, REVEL 0.19, MetaLR 0.25
- H22H (p.His22His), gnomAD 11-117986533-T-C, CADD 3.75
- G23E (p.Gly23Glu), NCI-TCGA Cosmic COSV5714, Variant assessed as somatic; moderate impact.
- G23R (p.Gly23Arg), TOPMed rs1352415686, REVEL 0.51, MetaLR 0.51
- G23W (p.Gly23Trp), gnomAD 11-117986534-G-T, REVEL 0.50, MetaLR 0.50
- G23G (p.Gly23Gly), rs2058000891, gnomAD 11-117988383-G-C, CADD 7.35
- T24K (p.Thr24Lys), rs2058000912, ClinGen CA382772516, ClinVar RCV002609377, ClinVar RCV004065815, AlphaMissense 0.14, MetaLR 0.37, Uncertain significance, Inborn genetic diseases; Inflammatory bowel disease 28
- T24T (p.Thr24Thr), rs560128585, gnomAD 11-117988386-A-C, CADD 8.54
- E25D (p.Glu25Asp), rs150140303, ClinGen CA6298827, ClinVar RCV000647212, ClinVar RCV001702540, REVEL 0.10, MetaLR 0.18, Benign, not provided; Inflammatory bowel disease 28
- E25Q (p.Glu25Gln), ExAC rs754393690, gnomAD rs754393690, MetaLR 0.29, MetaSVM -0.76
- E25E (p.Glu25Glu), gnomAD 11-117988389-G-A, CADD 4.08
- L26L (p.Leu26Leu), rs747730587, gnomAD 11-117988392-G-A, CADD 9.54
- P27L (p.Pro27Leu), rs755758777, ClinGen CA6298829, ClinVar RCV000330022, ClinVar RCV004021497, REVEL 0.50, MetaLR 0.45, Uncertain significance, Inborn genetic diseases; Inflammatory bowel disease 28
- P27P (p.Pro27Pro), gnomAD 11-117988395-C-T, CADD 4.65
- S28A (p.Ser28Ala), gnomAD 11-117988392-GC-G, CADD 25.70
- S28C (p.Ser28Cys), gnomAD 11-117988396-A-T, REVEL 0.31, MetaLR 0.42
- S28N (p.Ser28Asn), gnomAD 11-117988397-G-A, REVEL 0.08, MetaLR 0.28
- S28R (p.Ser28Arg), gnomAD 11-117988398-C-A, REVEL 0.08, MetaLR 0.23
- P29A (p.Pro29Ala), 1000Genomes rs201980658, TOPMed rs201980658, gnomAD rs201980658, REVEL 0.71, MetaLR 0.87, Uncertain significance, Inflammatory bowel disease 28
- P29P (p.Pro29Pro), gnomAD 11-117988401-T-G, CADD 7.84
- P30L (p.Pro30Leu), rs749622044, ClinGen CA6298831, ClinVar RCV001105571, ClinVar RCV003326540, REVEL 0.15, MetaLR 0.23, Conflicting interpretations, not provided; Inflammatory bowel disease 28
- P30P (p.Pro30Pro), rs747872407, gnomAD 11-117988404-G-A, CADD 1.35
- S31C (p.Ser31Cys), 1000Genomes rs201436588, gnomAD rs201436588, REVEL 0.25, MetaLR 0.45
- S31P (p.Ser31Pro), gnomAD 11-117988405-T-C, REVEL 0.37, MetaLR 0.39
- V32A (p.Val32Ala), gnomAD rs1310932449, REVEL 0.58, MetaLR 0.55
- V32L (p.Val32Leu), TOPMed rs920051155, gnomAD rs920051155, REVEL 0.47, MetaLR 0.39, Uncertain significance
- V32M (p.Val32Met), TOPMed rs920051155, gnomAD rs920051155, REVEL 0.65, MetaLR 0.68, Uncertain significance, Inborn genetic diseases
- V32V (p.Val32Val), rs377525753, gnomAD 11-117988410-G-A, CADD 11.60
- W33* (p.Trp33Ter), Ensembl rs1591260984
- W33C (p.Trp33Cys), TOPMed rs1281442597, gnomAD rs1281442597, REVEL 0.51, MetaLR 0.50
- W33R (p.Trp33Arg), NCI-TCGA TCGA novel, REVEL 0.40, MetaLR 0.16, Variant assessed as somatic; moderate impact.
- F34L (p.Phe34Leu), NCI-TCGA Cosmic COSV9992, 1000Genomes rs537603232, ExAC rs537603232, gnomAD rs537603232, REVEL 0.68, MetaLR 0.45, Variant assessed as somatic; moderate impact.
- E35Q (p.Glu35Gln), NCI-TCGA Cosmic COSV5714, MetaLR 0.24, MetaSVM -0.83, Variant assessed as somatic; moderate impact.
- E35V (p.Glu35Val), gnomAD rs1203213796, REVEL 0.38, MetaLR 0.27
- E35K (p.Glu35Lys), gnomAD 11-117988417-G-A, REVEL 0.13, MetaLR 0.22
- E35E (p.Glu35Glu), rs1565370559, gnomAD 11-117988419-A-G, CADD 13.80
- A36T (p.Ala36Thr), TOPMed rs1475635471, REVEL 0.61, MetaLR 0.50
- A36V (p.Ala36Val), ESP rs371081181, ExAC rs371081181, gnomAD rs371081181, MetaLR 0.48, MetaSVM -0.15
- A36A (p.Ala36Ala), gnomAD 11-117988422-A-G, CADD 11.60
- E37D (p.Glu37Asp), ESP rs375630665, TOPMed rs375630665, gnomAD rs375630665, REVEL 0.14, MetaLR 0.24
- E37Q (p.Glu37Gln), gnomAD 11-117988423-G-C, REVEL 0.09, MetaLR 0.17
- F38I (p.Phe38Ile), gnomAD rs1483446748, REVEL 0.39, MetaLR 0.23
- F38L (p.Phe38Leu), rs200175106, ClinGen CA6298836, ClinVar RCV001036342, 1000Genomes rs200175106, REVEL 0.17, MetaLR 0.19, Uncertain significance, Inflammatory bowel disease 28
- F38V (p.Phe38Val), gnomAD 11-117988426-T-G, REVEL 0.51, MetaLR 0.31
- F39L (p.Phe39Leu), gnomAD 11-117988431-C-G, REVEL 0.52, MetaLR 0.40
- H40Y (p.His40Tyr), gnomAD rs2058001533, REVEL 0.07, MetaLR 0.23
- H41R (p.His41Arg), gnomAD rs1265212565, REVEL 0.72, MetaLR 0.55
- H41Y (p.His41Tyr), NCI-TCGA Cosmic COSV5713, MetaLR 0.55, MetaSVM -0.07, Variant assessed as somatic; moderate impact.
- I42V (p.Ile42Val), ExAC rs761039534, gnomAD rs761039534, REVEL 0.21, MetaLR 0.25
- I42F (p.Ile42Phe), gnomAD 11-117988438-A-T, REVEL 0.46, MetaLR 0.46
- I42I (p.Ile42Ile), rs570833435, gnomAD 11-117988440-C-T, CADD 8.39
- L43I (p.Leu43Ile), NCI-TCGA Cosmic COSV9992, MetaLR 0.69, MetaSVM 0.43, Variant assessed as somatic; moderate impact.
- L43L (p.Leu43Leu), gnomAD 11-117988443-C-T, CADD 5.17
- H44Q (p.His44Gln), Ensembl rs1591261006
- H44Y (p.His44Tyr), gnomAD 11-117988444-C-T, REVEL 0.12, MetaLR 0.25
- H44R (p.His44Arg), gnomAD 11-117988445-A-G, REVEL 0.07, MetaLR 0.17
- W45R (p.Trp45Arg), gnomAD 11-117988447-T-C, REVEL 0.93, MetaLR 0.96
- W45G (p.Trp45Gly), gnomAD 11-117988447-T-G, REVEL 0.95, MetaLR 0.96
- T46A (p.Thr46Ala), rs112317511, ClinGen CA6298839, ClinVar RCV000524699, ClinVar RCV001701041, REVEL 0.12, MetaLR 0.15, Benign/Likely benign, Inflammatory bowel disease 28; not provided
- T46I (p.Thr46Ile), gnomAD 11-117988451-C-T, REVEL 0.13, MetaLR 0.22
- T46T (p.Thr46Thr), rs762792922, gnomAD 11-117988452-A-G, CADD 0.26
- P47A (p.Pro47Ala), gnomAD rs2058001692, REVEL 0.41, MetaLR 0.39
- P47R (p.Pro47Arg), rs2496772090, ClinGen CA382772856, ClinVar RCV002909639, Uncertain significance, Inflammatory bowel disease 28
- I48T (p.Ile48Thr), ExAC rs766359230, gnomAD rs766359230, REVEL 0.38, MetaLR 0.55
- I48I (p.Ile48Ile), rs140466541, gnomAD 11-117988458-C-T, CADD 6.47
- P49A (p.Pro49Ala), gnomAD 11-117988459-C-G, REVEL 0.10, MetaLR 0.28
- P49L (p.Pro49Leu), gnomAD 11-117988460-C-T, REVEL 0.10, MetaLR 0.31
- N50K (p.Asn50Lys), rs1041042952, ClinGen CA229440972, ClinVar RCV002741489, TOPMed rs1041042952, REVEL 0.17, MetaLR 0.22, Uncertain significance, Inflammatory bowel disease 28
- N50S (p.Asn50Ser), gnomAD 11-117988463-A-G, REVEL 0.08, MetaLR 0.28
- Q51R (p.Gln51Arg), TOPMed rs1196373193, gnomAD rs1196373193, REVEL 0.12, MetaLR 0.34
- Q51Q (p.Gln51Gln), rs759088730, gnomAD 11-117988467-G-A, CADD 0.96
- S52C (p.Ser52Cys), rs1366152604, ClinGen CA382772919, ClinVar RCV002609932, TOPMed rs1366152604, REVEL 0.38, MetaLR 0.46, Uncertain significance, Inflammatory bowel disease 28
- E53* (p.Glu53Ter), NCI-TCGA Cosmic COSV9992, Variant assessed as somatic; high impact.
- E53A (p.Glu53Ala), rs2134981745, ClinGen CA382772933, ClinVar RCV002000884, Ensembl rs2134981745, AlphaMissense 0.11, MetaLR 0.25, Uncertain significance, Inflammatory bowel disease 28
- S54I (p.Ser54Ile), TOPMed rs772899933, gnomAD rs772899933, MetaLR 0.30, MetaSVM -0.72, Uncertain significance
- S54N (p.Ser54Asn), TOPMed rs772899933, gnomAD rs772899933, REVEL 0.10, MetaLR 0.15, Uncertain significance
Public IL10RA analysis runs
- IL10RA analysis run — IL10RA (865 variants) — completed 2026-08-19